Investors & Media

Webcast ImageWebcast
GBT Investor Event to Review GBT440 Data in SCD Being Presented at EHA (Replay)
06/10/16 at 7:30 a.m. ET
GBT Investor Event to Review GBT440 Data in SCD Being Presented at EHA
Friday, June 10, 2016 7:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Supporting Materials
Download Event Supporting Material EHA GBT440 Presentation
EHA 2016 Poster: GBT440, a Novel HbS Polymerization Inhibitor, Increases Hb Oxygen Affinity and Results in a Rapid Improvement in Hemolysis and Anemia
EHA 2016 Poster: Pharmacokinetics (PK) and Pharmacodynamics (PD) of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Volunteers and SCD Patients
Corporate Profile
Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440... More >>
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$22.75
Change (%) Stock is Down 0.66 (2.82%)
Volume366,175
Data as of 09/23/16 4:00 p.m. ET
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation (September 2016)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
09/14/16Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders
Data Published in Physiological Reports Highlight the Potential of GBT440 to Improve Hypoxemia and Delay Pulmonary Fibrosis Progression SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced publication of preclinical data supporting the development of GBT440 for the treatment of ... 
Printer Friendly Version
09/06/16Global Blood Therapeutics Joins Sickle Cell Disease (SCD) Coalition in Support of SCD Community with Goal to Improve Treatment and Care
Coalition Report, ‘State of Sickle Cell Disease: 2016’ Uncovers Unmet Needs in SCD and Provides Strategies to Spur Positive Change SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that in connection with Sickle Cell Disease (SCD) Awareness Month, the company has joined the S... 
Printer Friendly Version
08/31/16Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will participate in two upcoming investor conferences. Following are details for each presentation: Wells Fargo Securities Healthcare Conference Date/T... 
Printer Friendly Version
08/10/16Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today reported business progress and financial results for the second quarter ended June 30, 2016. “We made important progress across our GBT440 development programs and strengthened our balance sheet with the completion of our financing in ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.